

**Susceptibility profiles and resistance genomics of *Pseudomonas aeruginosa* isolates from European ICUs participating in the ASPIRE-ICU trial**

**Gabriel TORRENS<sup>1</sup>, Thomas Ewout VAN DER SCHALK<sup>2</sup>, Sara CORTES-LARA<sup>1</sup>, Leen TIMBERMONT<sup>2</sup>, Ester del BARRIO-TOFIÑO<sup>1</sup>, Basil Britto XAVIER, Laura ZAMORANO<sup>1</sup>, Christine LAMMERS<sup>2</sup>, Omar ALI<sup>3</sup>, Alexey RUZIN<sup>3</sup>, Herman GOOSENS<sup>2</sup>, Samir KUMAR-SINGH<sup>2</sup>, Jan KLUYTMANS<sup>4</sup>, Fleur PALING<sup>4</sup>, R. Craig MACLEAN<sup>5</sup>, Thilo KOHLER<sup>6</sup>, C. LOPEZ-CAUSAPE<sup>1</sup>, Surbhi MALHOTRA-KUMAR<sup>2\*</sup>, Antonio OLIVER<sup>1\*</sup> on behalf of the ASPIRE-ICU study team**

<sup>1</sup> Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), CIBERINFEC, Palma de Mallorca, Spain

<sup>2</sup> Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium

<sup>3</sup> Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA

<sup>4</sup> University Medical Centre Utrecht, Utrecht University, The Netherlands

<sup>5</sup> University of Oxford, Department of Zoology, Oxford, UK

<sup>6</sup> Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.

**Running title:** *P. aeruginosa* resistance genomics in Europe

**Correspondence:** Antonio Oliver ([antonio.oliver@ssib.es](mailto:antonio.oliver@ssib.es))

## Abstract

**Objective.** To determine the susceptibility profiles and the resistome of *P. aeruginosa* isolates from European ICUs during a prospective cohort (ASPIRE-ICU). **Methods.** 723 isolates from respiratory samples or perianal swabs of 402 patients from 29 sites in 11 countries were studied. MICs for 12 antibiotics were determined by broth microdilution. Horizontally-acquired  $\beta$ -lactamases were analyzed through phenotypic and genetic assays. The first respiratory isolate from 105 patients providing such samples were analyzed through WGS, including the analysis of the resistome and a previously defined genotypic resistance score. Spontaneous mutant frequencies and genetic basis of hypermutation were assessed. **Results:** All agents except colistin showed resistance rates above 20%, including ceftolozane/tazobactam and ceftazidime/avibactam. 24.9% of the isolates were XDR, with a wide intercountry variation (0-62.5%). 13.2% of the isolates were classified as DTR (Difficult to Treat Resistance). 21.4% of the isolates produced ESBLs (mostly PER-1) or carbapenemases (mostly NDM-1, VIM-1/2 and GES-5). WGS showed that these determinants were linked to high-risk clones (particularly ST235 and ST654). WGS revealed a wide repertoire of mutation-driven resistance mechanisms, with multiple lineage-specific mutations. The most frequently mutated genes were *gyrA*, *parC*, *oprD*, *mexZ*, *nalD* and *ParS*, but only 2 of the isolates were hypermutable. Finally, a good accuracy of the genotypic score to predict susceptibility (91-100%) and resistance (94-100%) was documented. **Conclusions:** An overall high prevalence of resistance is documented European ICUs, but with a wide intercountry variability determined by the dissemination of XDR high-risk clones, arguing for the need of reinforcement of infection control measures.

## Introduction

The growing prevalence of nosocomial infections produced by MDR and particularly XDR *P. aeruginosa* strains is associated with significantly increased morbidity and mortality, since it compromises the available effective therapeutic options.<sup>1,2</sup> This increasing threat results from the extraordinary capacity of *P. aeruginosa* for developing resistance to nearly all available antibiotics, conferred by mutations in chromosomal genes and by a growing amount of transferable resistance determinants. Of particular concern are those coding for carbapenemases or extended-spectrum  $\beta$ -lactamases (ESBLs), frequently co-transferred with aminoglycoside-modifying enzymes determinants.<sup>3</sup> The dissemination of MDR/XDR global strains, the high-risk clones, in multiple hospitals worldwide adds further concern.<sup>4-8</sup> Moreover, beyond classical molecular epidemiology and phenotypically-targeted resistance mechanisms assessment, recent whole genome sequencing (WGS) studies are providing relevant information for building up the complex and evolving resistome of MDR/XDR *P. aeruginosa* high-risk clones.<sup>9-15</sup> On the other hand, the recent introduction of novel  $\beta$ -lactam- $\beta$ -lactamase inhibitor combinations, such as ceftolozane/tazobactam or ceftazidime/avibactam, which are quite stable against mutation-driven resistance mechanisms, partially alleviate the urgent clinical need of new agents for combating infections by MDR/XDR *P. aeruginosa*.<sup>16-18</sup> However, emergence of resistance to these antibiotics has been found rapidly after their introduction and should therefore be closely monitored.<sup>19,20</sup> Although susceptibility data from European countries is reported in some initiatives, such as the ECDC EARS-Net, information on the involved resistance mechanisms is scarce. Moreover, most genomic surveys so far have been performed at the single hospital or country level.<sup>13,21,22</sup> Thus, here we describe the first large scale survey of antimicrobial susceptibility profiles and resistome analysis from European ICUs. This work is part of the ASPIRE-ICU (Advanced Understanding of *Staphylococcus aureus* and *Pseudomonas aeruginosa* infections in Europe-Intensive Care Units) study<sup>23</sup> and has been presented as a poster in the 31<sup>st</sup> ECCMID.

## Material and Methods

### Clinical isolates, susceptibility testing and characterization of resistance mechanisms

A total of 723 isolates obtained from respiratory samples or perianal swabs (PAS) of 402 mechanically-ventilated ICU patients enrolled in the ASPIRE-ICU trial (NCT02413242) from 29 different sites in 11 different countries were studied. The trial lasted from 2016 to 2021, but most of the patients (313 of 402) were enrolled in 2019. As part of the ASPIRE-ICU protocol, PAS

and respiratory (endotracheal aspirate or sputum) samples for *P. aeruginosa* culture were obtained at ICU admission and twice weekly thereafter. From patients who were diagnosed with pneumonia, additional respiratory samples were collected at the day of diagnosis and 7 days post-infection. Peri-anal swabs in skimmed milk medium and untreated respiratory samples were stored at  $-80^{\circ}\text{C}$  until shipment to the Central lab at the University of Antwerp until further analysis. Culture of peri-anal swabs was performed by inoculating the swabs directly on CHROMID *P. aeruginosa* Agar (BioMérieux, France) and blood agar (BBL®Columbia II Agar Base (BD Diagnostics, USA) supplemented with 5% defibrinated horse blood (TCS Bioscience, UK)). Patient respiratory samples were blended (30,000 rpm, probe size 8 mm, steps of 10 s, max 60 s in total), diluted 1:1 v/v with Lysomucil (10% Acetylcysteine solution) (Zambon S.A, Belgium) and incubated for 30 min at  $37^{\circ}\text{C}$  with 10 s vortexing every 15 min. Followed by culture on CHROMID *P. aeruginosa* Agar and blood agar. Plates were incubated at  $37^{\circ}\text{C}$  for 24 h. Plates without growth were further incubated for 48 h and 72 h. Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS, Bruker Daltonics) was used to identify *P. aeruginosa* isolates, which were stored at  $-80^{\circ}\text{C}$  until further use.

MICs for a panel of 12 antipseudomonal agents were determined by broth microdilution using EUCAST 2021 breakpoints ([www.eucast.org](http://www.eucast.org)) at Hospital Son Espases (Palma de Mallorca, Spain). MDR, XDR and PDR profiles were defined as suggested by Magiorakos *et al.* (2012).<sup>24</sup> However, according to current EUCAST instructions only truly resistant (R) isolates were considered, as opposed to previous recommendations to use I+R. Additionally, difficult to treat resistance (DTR) phenotypes were defined as described previously.<sup>25</sup> The occurrence of horizontally-acquired carbapenemases and Extended Spectrum  $\beta$ -lactamases (ESBLs) was analysed through phenotypic and genetic (PCR and sequencing) assays.<sup>12</sup> Imipenem and ceftazidime resistance cloxacillin inhibition test was initially used for screening chromosomal  $\beta$ -lactam resistance mechanisms (inactivation of OprD and/or the overexpression of AmpC) and was followed by double-disk synergy tests (DDST) for the detection of class B carbapenemases (EDTA) and/or class A carbapenemases or ESBLs (clavulanic acid), following previously established procedures.<sup>12</sup>

#### **Whole genome sequencing and resistome analysis**

Whole genome sequencing was performed on the first respiratory isolate from each of the patients (n=105).

**Library preparation and whole-genome sequencing (WGS).** Strains were cultured overnight at 37°C on Mueller Hinton agar plates, transferred to Mueller Hinton broth and incubated overnight at 37 °C. DNA was extracted from 2ml of culture using the MagAttract HMW DNA Kit (Qiagen, Germany) according to manufacturer's instructions. Multiplexed DNA libraries were prepared using the Nextera XT Library and Sample Preparation Kit followed by v2 2x150-bp paired-end sequencing on a MiSeq instrument (Illumina Inc., USA). The primary sequencing analysis was done using BacPipe v.2.6.1 and checkM was used for determining cross contamination.

**De novo assembly.** Paired-end reads were *de novo* assembled using SPAdes v3.13.1 (<http://cab.spbu.ru/files/release3.13.1/>)

**Variant calling.** Previously defined and validated protocols were used with slight modifications.<sup>26</sup> Briefly, paired-ended reads were mapped to the *P. aeruginosa* PAO1 reference genome (NC\_002516.2) with Bowtie 2 v2.2.4 and pileup and raw files were obtained by using SAMtools v0.1.16 and PicardTools v1.140, using the Genome Analysis Toolkit (GATK) v3.4-46 for realignment around InDels. From the raw files, SNPs were extracted if they met the following criteria: a quality score (Phred-scaled probability of the samples reads being homozygous reference) of at least 50, a root-mean-square (RMS) mapping quality of at least 25 and a coverage depth of at least 3 reads, excluding all ambiguous variants. MicroInDels were extracted from the total pileup files when meeting the following criteria: a quality score of at least 500, a RMS mapping quality of at least 25 and support from at least one-fifth of the covering reads. Filtered files were converted to vcf and SNPs and InDels were annotated with SnpEff v4.2.<sup>27</sup> Gene absence was also investigated using the SeqMonk program (<https://www.bioinformatics.babraham.ac.uk/projects/seqmonk/>). Finally, as different sequence variants of *OprD* have been described<sup>28</sup>, the *de novo* assemblies were used to first classify the *oprD* gene according to their similarity to PAO1, LESB58, UCBP-PA14, MTB-1, FRD1 or F23197 reference sequences and to further investigate their structural integrity. The presence of horizontally-acquired antimicrobial resistance determinants was also investigated using the web tool ResFinder (<https://cge.cbs.dtu.dk/services/ResFinder/>).

**Assessment of *P. aeruginosa* genotypic resistance scores.** The presence of acquired resistance determinants and mutations located within 40 chromosomal genes involved in mutational resistance (*gyrB*, *mexR*, *mexA*, *mexB*, *oprM*, *ampDh3*, *oprD*, *parS*, *parR*, *mexY*, *mexX*, *mexZ*, *galU*, *mexS*, *mexT*, *mexE*, *mexF*, *oprN*, *dacB*, *gyrA*, *nalD*, *nalC*, *dacC*, *pbpA*, *mpl*,

*ampR*, *ampC*, *fusA1*, *ftsI*, *ampD*, *oprJ*, *mexD*, *mexC*, *nfxB*, *pmrA*, *pmrB*, *parC*, *parE*, *armZ*, *ampDh2*) were scored for determining the genotypic resistance scores values.<sup>29</sup>

**Spontaneous mutant frequencies and characterization of mutator strains.** The frequencies of mutation to rifampicin (300 mg/L) resistance were determined as described previously.<sup>30</sup> For each strain, independent aliquots containing approximately 10<sup>3</sup> cells were inoculated into five flasks containing 10 ml of Mueller-Hinton broth and incubated at 37°C and 180 rpm for 16 to 18 h and serial 1:10 dilutions were plated on Mueller-Hinton agar plates and Mueller-Hinton agar plates supplemented with 300 mg/L of rifampicin. Mutant frequencies were then calculated by dividing the median numbers of mutants by the median numbers of total cells. The breakpoint used to define hypermutable strains was a frequency of mutation to rifampicin resistance of  $>2 \times 10^{-7}$ , as established previously.<sup>30</sup> Additionally, as a control, frequencies of mutants to rifampicin resistance were determined with reference strain PAO1 and its DNA mismatch repair deficient *mutS* derivative (PAOMS)<sup>30</sup>. To explore the genetic basis for the mutator phenotypes, complementation studies were performed with all hypermutable strains. Plasmid pUCPMS harbouring PAO1 wild-type *mutS*, plasmid pUCPML harbouring PAO1 wild-type *mutL*, and plasmid pUCP24, a control cloning vector, were electroporated into the hypermutable isolates and transformants were selected on Luria-Bertani agar plates containing 50 mg/L of gentamicin.<sup>30</sup> Complementation was demonstrated by reversion of the increased rate of mutation to rifampicin resistance in two independent transformant colonies for each strain. Additionally, the genetic basis of hypermutation was investigated from whole genome sequence data, through the analysis of an exhaustive panel of 15 mutator genes (mutome) as described previously.<sup>31</sup>

## **Data availability**

Sequence files will be deposited in the ASPIRE-ICU NCBI BioProject PRJNA768775

## **Results**

Figure 1 shows the antimicrobial susceptibility data considering a single isolate from each of the 402 enrolled patients. When available, the first respiratory isolate was considered (n=105) whereas the first PAS isolate was used for those patients showing no positive respiratory samples (n=297). Lowest resistance rates were documented for colistin (1.2%),

distantly followed by amikacin (12.9%). Up to 28.4% of the isolates were resistant to tobramycin and 37.4% to ciprofloxacin. Among  $\beta$ -lactams, resistance rates were highest for imipenem (48%), followed by piperacillin/tazobactam (30.6%), meropenem (27.6%), cefepime (27.1%) and ceftazidime (26.4%). It is noteworthy that resistance rates for the novel antipseudomonal combinations ceftolozane/tazobactam (23.4%) and ceftazidime/avibactam (21.4%) were not much lower. Moreover, aztreonam showed similar resistance rates (21.4%). Up to 32.9% of the isolates were MDR, 24.9% XDR and 0.7% PDR. On the other hand, 13.2% were classified as DTR. Figure 2 shows the distribution of the resistance profiles in the different countries. The prevalence of XDR phenotype was highest in hospitals from Serbia (62.5%), followed by those in Hungary (35.3%), Bulgaria (27.5%) and Czech Republic (15.8%). XDR isolates were not detected among isolates from Germany, UK, Turkey and Estonia.

Figure S1 shows the susceptibility data for the 402 isolates according to sample types. As shown, resistance rates were higher for respiratory isolates than for PAS isolates. For instance, up to 41.9% of the respiratory isolates showed an XDR profile, whereas only 18.9% of PAS isolates did. However, it appears not to be an intrinsic feature of the sample type itself, since an analysis of paired isolates from the 45 patients contributing both respiratory and PAS isolates showed no major differences in resistance rates (Figure 3a).

Another aspect analyzed was the potential emergence of resistance during the course of the colonization/infection. For this purpose, susceptibility data were analyzed for 118 early (first) and late (last) pairs of isolates from 100 patients showing multiple PAS and/or respiratory samples and results are shown in Figure 3b. An overall tendency for increased resistance was observed with the highest (>10%) increase for imipenem and piperacillin/tazobactam.

The  $\beta$ -lactam resistance mechanisms were analyzed through phenotypic and molecular (PCR + sequencing) assays. As shown in Figure 4,  $\beta$ -lactam resistance mechanisms were found in close to one third (30.6%) of the isolates, 21.4% showing acquired  $\beta$ -lactamases and 9.2% only mutation-driven resistance mechanism (positive inhibition of ceftazidime resistance with cloxacillin suggesting AmpC hyperproduction, and/or positive inhibition of imipenem resistance with cloxacillin suggesting OprD inactivation). Regarding horizontally acquired  $\beta$ -lactamases, 48.6% of the isolates producing such enzymes showed a PER-1 ESBL, alone or together with an OXA-10. Besides PER-1, another single isolate from Bulgaria produced a VEB-1 ESBL. Regarding carbapenemases, 21.4% of the isolates producing horizontally-acquired  $\beta$ -lactamases produced VIM (either VIM-1 or VIM-2), 17.8% GES-5, 15.5% NDM-1, and 2.4%

IMP-7. It is noteworthy that 9.5% of the isolates producing acquired  $\beta$ -lactamases coproduced NDM-1 and GES-5.

WGS was performed on the 105 respiratory isolates. MLST analysis revealed up to 47 different STs, with ST235, considered to be a high-risk clone, being by far the most frequent one, detected in 33 isolates. Besides ST235, 15 clones/clonal complexes were detected in at least 2 patients (2 to 7). Table 1 shows the distribution of the main horizontally-acquired and mutation driven resistance mechanisms for the complete collection of isolates and for those clones detected in at least 2 patients. Conversely, Figure 5 summarizes the resistome of the 54 (51.4%) MDR/XDR/PDR isolates and Table S1 provides susceptibility data and resistome analysis for all tested isolates. Globally, ST235 was the clone more frequently associated with horizontally-acquired and mutation-driven resistance mechanisms and therefore strongly associated with MDR/XDR/PDR profiles, and it was frequently detected in patients from Serbian hospitals. The detection of acquired  $\beta$ -lactamases was concordant with the above PCR analysis. All PER-1 and VIM-2 producing isolates belonged to ST235, whereas GES-5 was detected among ST235 and ST654 isolates. Moreover, all NDM-1 producing isolates belonged to ST654 and coproduced GES-5. The most frequent horizontally-acquired aminoglycoside modifying enzyme was AadB being detected in 25.7% of the isolates, mainly from ST235 and ST175 clones. Regarding the mutational resistome, the most frequently mutated target included the QRDR regions of *gyrA* (52.4% of the isolates) or *parC* (41.9%), the carbapenem porin OprD (49.5%) the negative regulator of MexXY efflux pump MexZ (44.8%), the negative regulator of MexAB-OprM NalD (27.6%) and ParS from the ParRS two component system (21.9%) (Table 1). As shown in Figure 5, specific resistome patterns were observed for the different MDR/XDR/PDR clones. It is noteworthy that ST235 isolates from Serbian hospitals showed multiple different resistome signatures including both horizontally-acquired and mutation-driven resistance. On the other hand, a single resistome pattern was observed for ST654, the second most frequent genotype. Also noteworthy, ST175 isolates from Spain and Hungary showed the same previously described OprD and *ampR* mutations responsible for  $\beta$ -lactam resistance in this clone.

In order to determine whether frequent mutation-driven resistance was linked to mutator phenotypes, spontaneous mutant frequencies were determined for the 105 respiratory isolates and results are shown in Figure 6. Only 2 (1.9%) of the isolates showed a mutator phenotype and only one of them showed an XDR profile associated with a large number of resistance mutations, while the other showed only imipenem resistance due to an *oprD* mutation.



Complementation assays with wild-type mutator genes revealed that one of the isolates was deficient in *mutS* and the other in *mutL*. Genomic analysis of a previously described panel of genes involved in mutator phenotypes (mutome) revealed the presence of specific mutations in *mutS* (T493P) and *mutL* (A272D), respectively. Curiously, the *mutL* mutation originated a novel MLST allele within CC298 clonal complex. On the other hand, diverse polymorphisms apparently not involved in increased mutation rates were documented in mutator genes of wild-type isolates (Table 1S).

Finally, to assess the correlation between phenotypes and genotypes of antibiotic resistance, a recently described genotypic resistance score was applied for ceftazidime, ceftolozane/tazobactam, meropenem, ciprofloxacin and tobramycin, and results are presented in Table 2. Three of the 105 isolates were not assessable since they were genomic outliers. For the remaining 102 isolates the phenotypic-genotypic correlation was high. A genotypic score below 0.5 predicted susceptibility in 100% of the isolates for ceftazidime, ceftolozane/tazobactam, ciprofloxacin and tobramycin and in 90.9% for meropenem. Conversely, a genotypic score equal or higher than 1 predicted resistance in 93.9% (meropenem) to 100% (tobramycin and ceftolozane/tazobactam) of the cases. Additionally, from 3 to 12 isolates, depending on the antibiotic, showed scores  $\geq 0.5$  and  $< 1$  and were classified as undetermined resistance genotype.

## Discussion

The susceptibility profiles to a panel of 12 antipseudomonal agents was evaluated in over four hundred *P. aeruginosa* isolates from the ICUs of hospitals from 11 European countries. Nearly one fourth of the isolates met the ECDC/CDC XDR criteria<sup>24</sup> but a wide geographic variation was found, with some countries reporting over 60% of XDR isolates while others had none. In addition to the classical MDR/XDR/PDR ECDC/CDC definitions, recently proposed DTR criteria (resistance to all first line agents including classical antipseudomonal  $\beta$ -lactams and fluoroquinolones) were also applied<sup>25</sup>, since direct comparisons between both definitions are currently lacking. DTR prevalence was established at 13.2% in European ICUs, well above the 2.1% reported for US hospitals in a recent study<sup>25</sup>. Still, prevalence of DTR phenotypes was nearly half of that of XDR phenotypes. Indeed, up to 49.5% of XDR isolates were classified as non-DTR, but 100% of DTR isolates were classified as XDR (Table S1). A high prevalence (over 20%) of resistance to the novel  $\beta$ -lactam  $\beta$ -lactamase inhibitor combinations was observed as well. Moreover, up to 83% of the XDR isolates were resistant to ceftolozane/tazobactam and/or ceftazidime/avibactam. These findings contrast with those

documented in some recent national European surveys <sup>13,22,32</sup> and is correlated with the high prevalence of horizontally-acquired broad spectrum  $\beta$ -lactamases (ESBLs and/or carbapenemases) in our isolate collection. ICU isolates, and particularly those recovered from the respiratory tract, were however associated with higher resistance rates in previous studies.<sup>13</sup> Similar to XDR profiles, we observed a wide inter-country variation in the distribution of such concerning  $\beta$ -lactamase enzymes, with specific countries showing an extremely high number and diversity of isolates producing horizontally-acquired  $\beta$ -lactamases, while their presence was not detected in several other countries. One of the limitations of our survey is, however, the wide variation of patients and strains contributed by each of the participating countries ranging from 4 to 104 (Figure 2).

One intriguing finding of the study was that respiratory isolates showed more frequent resistant phenotypes than PAS isolates. Although the investigation of the underlying factors falls out of the scope of this work and will be addressed separately in the clinical part of the ASPIRE-ICU trial <sup>23</sup>, it appears not to be an intrinsic feature of the sample origin itself, since an analysis of paired isolates from the patients contributing both respiratory and PAS isolates showed no major differences in resistance rates. Thus, differences should reside in the characteristics of patients contributing only PAS isolates but not respiratory samples and may potentially include nosocomial acquisition, antibiotic exposure, length of admission, or ICU characteristics among others.

In addition to the high primary resistance rates documented, a clear tendency towards increased resistance during the course of the colonization/infection was evidenced. These findings are in agreement with previous experiences and likely reflect within host evolution of resistance during antibiotic exposure. <sup>33–35</sup> Interestingly, this trend was not observed for the novel  $\beta$ -lactam  $\beta$ -lactamase inhibitor combinations, consistently with their reported higher stability against *P. aeruginosa* mutation-driven resistance mechanisms. <sup>18</sup>

WGS resistome analysis of respiratory isolates showed a high proportion and diversity of horizontally-acquired resistance genes and mutations, frequently linked to major international widespread high-risk clones. <sup>5,8</sup> Indeed, ST235 was particularly dominant and was found to be associated with multiple horizontally-acquired  $\beta$ -lactamases as well as with diverse patterns of mutation-driven resistance, even among isolates from a single center, denoting the dissemination of multiple independent ST235 lineages. One remarkable finding was the coproduction of NDM-1 class B and GES-5 class A carbapenemases among ST654 isolates, apparently not previously described so far. <sup>8</sup>

A vast repertoire of resistance mutations was also evidenced, with multiple genes including *oprD*, *gyrA*, *parC*, *mexZ*, *nalD* and *parS* being mutated among over 20 to 50 percent of the isolates, indicating that they are under strong selective pressure. However, with the exception of classical QRDR mutations, all others were clone specific. Interestingly, previously described *oprD* and *ampR* specific mutations responsible for  $\beta$ -lactam resistance in ST175 isolates widely disseminated in Spanish hospitals <sup>9,12,13</sup> were also identified in the single isolate from this clone recovered from a patient admitted to a hospital in Hungary. Conversely, widespread clone ST235 was associated with multiple different resistance mutations in *oprD*, *mexZ*, or MexAB-OprM regulators (*mexR*, *nalC* or *nalD*) even among isolates from a single hospital.

In order to determine whether frequent mutation-driven resistance was linked to mutator phenotypes, spontaneous mutant frequencies were determined, but only 2% of the isolates were *mutS* or *mutL* deficient mutators. This low prevalence of mutators among *P. aeruginosa* ICU respiratory isolates is in agreement with a previous study in a single Spanish ICU <sup>36</sup> and contrasts with the very high prevalence (30-60%) of mutators documented in chronic respiratory infections. <sup>30,37-39</sup> Strong association with mutation-driven resistance leading to an XDR phenotype was only evidenced in one of the two patients. In the other, only mutation-driven carbapenem resistance was evidenced. Curiously, in this patient the *mutL* mutation originated a novel MLST allele as described previously for other *mutL* deficient mutators. <sup>40</sup>

Finally, we attempted to assess whether the resistance genotype correlated well with the susceptibility phenotypes, and for this purpose we used a recently described genotypic resistance score that had been developed using a Spanish multicenter cohort. <sup>29</sup> Overall, we observed a good capability of the genotypic score to predict susceptibility (90.9 to 100%) and resistance (93.9-100%) to 5 antipseudomonal agents in this international cohort. These scores were quite similar to those previously documented for the Spanish collection, confirming a broad applicability of the described scoring system. The lowest performance was however documented, as in the previous study, for the prediction of meropenem resistance. Indeed, unlike the other agents, the assessment of meropenem phenotype-genotype correlation is complicated by the existence of an I category (MICs 4-8), that microbiologically correlates with a non-wildtype population (low level resistance).

In summary, an overall high prevalence of antimicrobial resistance is documented among *P. aeruginosa* isolates from European ICUs. However, a high inter-country variability was documented, with wide dissemination of ESBL- and/or carbapenemase- producing high-risk

XDR clones in some of them, arguing for the need of reinforcement of infection control measures.

## **Acknowledgment**

This study was conducted under the auspices of the European Study Group on Antimicrobial Resistance Surveillance (ESGARS) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).

## **Funding**

This work was supported by the Innovative Medicines Initiative Joint Undertaking under COMBACTE-MAGNET (Combating Bacterial Resistance in Europe-Molecules against Gram-negative Infections, grant agreement no. 115737) and COMBACTE-NET (Combating Bacterial Resistance in Europe-Networks, grant agreement no. 115523), resources of which are composed of financial contribution from the European Union's Seventh Framework Program (FP7/2007-2013) and EFPIA companies' in kind contribution. AO is also supported by Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016) and grants PI18/00076 and PI21/00017.

## **Transparency declaration**

Omar Ali and Alexey Ruzin are employees of AstraZeneca. All other authors none to declare

## **References**

1. Juan C, Peña C, Oliver A. Host and Pathogen Biomarkers for Severe *Pseudomonas aeruginosa* Infections. *J Infect Dis* 2017; **215**: S44–51. Available at: <https://pubmed.ncbi.nlm.nih.gov/28375513/>. Accessed August 11, 2021.
2. Horcajada JP, Montero M, Oliver A, *et al.* Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant *Pseudomonas aeruginosa* Infections. *Clin Microbiol Rev* 2019; **32**. Available at: <https://pubmed.ncbi.nlm.nih.gov/31462403/>. Accessed August 11, 2021.
3. Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii*: Mechanisms and epidemiology. *Int J Antimicrob Agents* 2015; **45**: 568–85. Available at: <https://pubmed.ncbi.nlm.nih.gov/25857949/>. Accessed August 11, 2021.

365 4. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of  
366 high-risk clones in the dissemination of antibiotic resistance. *FEMS Microbiol Rev* 2011; **35**:  
367 736–55. Available at: <https://pubmed.ncbi.nlm.nih.gov/21303394/>. Accessed August 11, 2021.

368 5. Oliver A, Mulet X, López-Causapé C, *et al.* The increasing threat of *Pseudomonas*  
369 *aeruginosa* high-risk clones. *Drug Resist Updat* 2015; **21–22**: 41–59.

370 6. Turton JF, Wright L, Underwood A, *et al.* High-Resolution Analysis by Whole-Genome  
371 Sequencing of an International Lineage (Sequence Type 111) of *Pseudomonas aeruginosa*  
372 Associated with Metallo-Carbapenemases in the United Kingdom Diekema DJ, ed. *J Clin*  
373 *Microbiol* 2015; **53**: 2622–31. Available at: <https://pubmed.ncbi.nlm.nih.gov/26041902/>.  
374 Accessed August 11, 2021.

375 7. Treepong P, Kos VN, Guyeux C, *et al.* Global emergence of the widespread *Pseudomonas*  
376 *aeruginosa* ST235 clone. *Clin Microbiol Infect* 2018; **24**: 258–66. Available at:  
377 <https://pubmed.ncbi.nlm.nih.gov/28648860/>. Accessed February 3, 2021.

378 8. del Barrio-Tofiño E, López-Causapé C, Oliver A. *Pseudomonas aeruginosa* epidemic high-  
379 risk clones and their association with horizontally-acquired  $\beta$ -lactamases: 2020 update. *Int J*  
380 *Antimicrob Agents* 2020; **56**: 106196. Available at: <https://pubmed.ncbi.nlm.nih.gov/33045347/>.  
381 Accessed August 11, 2021.

382 9. Cabot G, López-Causapé C, Ocampo-Sosa AA, *et al.* Deciphering the Resistome of the  
383 Widespread *Pseudomonas aeruginosa* Sequence Type 175 International High-Risk Clone  
384 through Whole-Genome Sequencing. *Antimicrob Agents Chemother* 2016; **60**: 7415–23.  
385 Available at: <https://pubmed.ncbi.nlm.nih.gov/27736752/>. Accessed February 3, 2021.

386 10. Jaillard M, van Belkum A, Cady KC, *et al.* Correlation between phenotypic antibiotic  
387 susceptibility and the resistome in *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* 2017; **50**:  
388 210–8. Available at: <https://pubmed.ncbi.nlm.nih.gov/28554735/>. Accessed August 11, 2021.

389 11. Kos VN, Déraspe M, McLaughlin RE, *et al.* The Resistome of *Pseudomonas aeruginosa* in  
390 Relationship to Phenotypic Susceptibility. *Antimicrob Agents Chemother* 2015; **59**: 427–36.  
391 Available at: <https://pubmed.ncbi.nlm.nih.gov/25367914/>. Accessed August 11, 2021.

392 12. del Barrio-Tofiño E, López-Causapé C, Cabot G, *et al.* Genomics and Susceptibility Profiles  
393 of Extensively Drug-Resistant *Pseudomonas aeruginosa* Isolates from Spain. *Antimicrob Agents*  
394 *Chemother* 2017; **61**. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/28874376>. Accessed  
395 July 12, 2019.

- 396 13. del Barrio-Tofiño E, Zamorano L, Cortes-Lara S, *et al.* Spanish nationwide survey on  
397 *Pseudomonas aeruginosa* antimicrobial resistance mechanisms and epidemiology. *J Antimicrob*  
398 *Chemother* 2019; **74**: 1825–35. Available at: <https://pubmed.ncbi.nlm.nih.gov/30989186/>.  
399 Accessed August 11, 2021.
- 400 14. López-Causapé C, Cabot G, del Barrio-Tofiño E, *et al.* The Versatile Mutational Resistome  
401 of *Pseudomonas aeruginosa*. *Front Microbiol* 2018; **9**. Available at:  
402 <https://pubmed.ncbi.nlm.nih.gov/29681898/>. Accessed August 11, 2021.
- 403 15. Pelegrin AC, Palmieri M, Mirande C, *et al.* *Pseudomonas aeruginosa*: a clinical and  
404 genomics update. *FEMS Microbiol Rev* 2021. Available at:  
405 <https://pubmed.ncbi.nlm.nih.gov/33970247/>. Accessed August 11, 2021.
- 406 16. van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-  
407 generation  $\beta$ -Lactam/ $\beta$ -Lactamase Inhibitor Combinations Saravolatz LD, ed. *Clin Infect Dis*  
408 2016; **63**: 234–41. Available at: <https://pubmed.ncbi.nlm.nih.gov/27098166/>. Accessed August  
409 11, 2021.
- 410 17. Torrens G, Cabot G, Ocampo-Sosa AA, *et al.* Activity of ceftazidime-avibactam against  
411 clinical and isogenic laboratory *Pseudomonas aeruginosa* isolates expressing combinations of  
412 most relevant  $\beta$ -lactam resistance mechanisms. *Antimicrob Agents Chemother* 2016; **60**: 6407–  
413 10. Available at: <https://pubmed.ncbi.nlm.nih.gov/27480848/>. Accessed February 8, 2021.
- 414 18. Moya B, Zamorano L, Juan C, *et al.* Activity of a New Cephalosporin, CXA-101 (FR264205),  
415 against  $\beta$ -Lactam-Resistant *Pseudomonas aeruginosa* Mutants Selected In Vitro and after  
416 Antipseudomonal Treatment of Intensive Care Unit Patients. *Antimicrob Agents Chemother*  
417 2010; **54**: 1213–7. Available at: <https://pubmed.ncbi.nlm.nih.gov/20086158/>. Accessed August  
418 11, 2021.
- 419 19. Haidar G, Philips NJ, Shields RK, *et al.* Ceftolozane-Tazobactam for the Treatment of  
420 Multidrug-Resistant *Pseudomonas aeruginosa* Infections: Clinical Effectiveness and Evolution of  
421 Resistance. *Clin Infect Dis* 2017; **65**: 110–20. Available at:  
422 <https://pubmed.ncbi.nlm.nih.gov/20086158/>. Accessed August 11, 2021.
- 423 20. Fraile-Ribot PA, Cabot G, Mulet X, *et al.* Mechanisms leading to in vivo  
424 ceftolozane/tazobactam resistance development during the treatment of infections caused by  
425 MDR *Pseudomonas aeruginosa*. *J Antimicrob Chemother* 2018; **73**: 658–63. Available at:  
426 <https://pubmed.ncbi.nlm.nih.gov/29149337/>. Accessed August 11, 2021.

21. Pelegrin AC, Saharman YR, Griffon A, *et al.* High-Risk International Clones of Carbapenem-Nonsusceptible *Pseudomonas aeruginosa* Endemic to Indonesian Intensive Care Units: Impact of a Multifaceted Infection Control Intervention Analyzed at the Genomic Level Gilligan P, ed. *MBio* 2019; **10**. Available at: <https://pubmed.ncbi.nlm.nih.gov/31719179/>. Accessed August 11, 2021.
22. Giani T, Arena F, Pollini S, *et al.* Italian nationwide survey on *Pseudomonas aeruginosa* from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. *J Antimicrob Chemother* 2018; **73**: 664–71. Available at: <https://pubmed.ncbi.nlm.nih.gov/29216350/>. Accessed August 11, 2021.
23. Paling FP, Troeman DPR, Wolkewitz M, *et al.* Rationale and design of ASPIRE-ICU: A prospective cohort study on the incidence and predictors of *Staphylococcus aureus* and *Pseudomonas aeruginosa* pneumonia in the ICU. *BMC Infect Dis* 2017; **17**: 643. Available at: <https://pubmed.ncbi.nlm.nih.gov/28946849/>. Accessed August 11, 2021.
24. Magiorakos A-P, Srinivasan A, Carey RB, *et al.* Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 2012; **18**: 268–81. Available at: <https://linkinghub.elsevier.com/retrieve/pii/S1198743X14616323>. Accessed February 3, 2021.
25. Kadri SS, Adjemian J, Lai YL, *et al.* Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. *Clin Infect Dis* 2018; **67**: 1803–14. Available at: <https://pubmed.ncbi.nlm.nih.gov/30052813/>. Accessed August 11, 2021.
26. Marvig RL, Sommer LM, Molin S, *et al.* Convergent evolution and adaptation of *Pseudomonas aeruginosa* within patients with cystic fibrosis. *Nat Genet* 2015; **47**: 57–64. Available at: <https://pubmed.ncbi.nlm.nih.gov/25401299/>. Accessed August 11, 2021.
27. Cingolani P, Platts A, Wang LL, *et al.* A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly (Austin)* 2012; **6**: 80–92. Available at: <https://pubmed.ncbi.nlm.nih.gov/22728672/>. Accessed August 11, 2021.
28. Sanbongi Y, Shimizu A, Suzuki T, *et al.* Classification of OprD sequence and correlation with antimicrobial activity of carbapenem agents in *Pseudomonas aeruginosa* clinical isolates collected in Japan. *Microbiol Immunol* 2009; **53**: 361–7. Available at:

458 <https://pubmed.ncbi.nlm.nih.gov/19563394/>. Accessed January 26, 2022.

459 29. Cortes-Lara S, Barrio-Tofiño E del, López-Causapé C, *et al.* Predicting *Pseudomonas*  
460 *aeruginosa* susceptibility phenotypes from whole genome sequence resistome analysis. *Clin*  
461 *Microbiol Infect* 2021. Available at: <https://pubmed.ncbi.nlm.nih.gov/34015532/>. Accessed  
462 August 11, 2021.

463 30. Mena A, Smith EE, Burns JL, *et al.* Genetic adaptation of *Pseudomonas aeruginosa* to the  
464 airways of cystic fibrosis patients is catalyzed by hypermutation. *J Bacteriol* 2008; **190**: 7910–7.  
465 Available at: <https://pubmed.ncbi.nlm.nih.gov/18849421/>. Accessed August 11, 2021.

466 31. López-Causapé C, Sommer LM, Cabot G, *et al.* Evolution of the *Pseudomonas aeruginosa*  
467 mutational resistome in an international Cystic Fibrosis clone. *Sci Rep* 2017; **7**: 5555. Available  
468 at: <https://pubmed.ncbi.nlm.nih.gov/28717172/>. Accessed August 11, 2021.

469 32. García-Fernández S, García-Castillo M, Melo-Cristino J, *et al.* In vitro activity of ceftolozane-  
470 tazobactam against Enterobacterales and *Pseudomonas aeruginosa* causing urinary, intra-  
471 abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP  
472 multicenter study. *Int J Antimicrob Agents* 2020; **55**: 105887. Available at:  
473 <https://pubmed.ncbi.nlm.nih.gov/34015532/>. Accessed August 11, 2021.

474 33. Juan C, Gutierrez O, Oliver A, *et al.* Contribution of clonal dissemination and selection of  
475 mutants during therapy to *Pseudomonas aeruginosa* antimicrobial resistance in an intensive  
476 care unit setting. *Clin Microbiol Infect* 2005; **11**: 887–92. Available at:  
477 <https://pubmed.ncbi.nlm.nih.gov/16216103/>. Accessed August 11, 2021.

478 34. Solé M, Fàbrega A, Cobos-Trigueros N, *et al.* In vivo evolution of resistance of  
479 *Pseudomonas aeruginosa* strains isolated from patients admitted to an intensive care unit:  
480 Mechanisms of resistance and antimicrobial exposure. *J Antimicrob Chemother* 2015; **70**:  
481 3004–13. Available at: <https://pubmed.ncbi.nlm.nih.gov/26260130/>. Accessed August 11, 2021.

482 35. Wheatley R, Diaz Caballero J, Kapel N, *et al.* Rapid evolution and host immunity drive the  
483 rise and fall of carbapenem resistance during an acute *Pseudomonas aeruginosa* infection. *Nat*  
484 *Commun* 2021; **12**: 2460. Available at: <https://pubmed.ncbi.nlm.nih.gov/33911082/>. Accessed  
485 August 11, 2021.

486 36. Gutiérrez O, Juan C, Pérez JL, Oliver A. Lack of Association between Hypermutation and  
487 Antibiotic Resistance Development in *Pseudomonas aeruginosa* Isolates from Intensive Care  
488 Unit Patients. *Antimicrob Agents Chemother* 2004; **48**: 3573–5. Available at:



489 <https://pubmed.ncbi.nlm.nih.gov/15328130/>. Accessed August 11, 2021.

490 37. Oliver A, Cantón R, Campo P, *et al.* High frequency of hypermutable *Pseudomonas*  
491 *aeruginosa* in cystic fibrosis lung infection. *Science* (80- ) 2000; **288**: 1251–3. Available at:  
492 <https://pubmed.ncbi.nlm.nih.gov/10818002/>. Accessed August 11, 2021.

493 38. Macià MD, Blanquer D, Togores B, *et al.* Hypermutation is a key factor in development of  
494 multiple-antimicrobial resistance in *Pseudomonas aeruginosa* strains causing chronic lung  
495 infections. *Antimicrob Agents Chemother* 2005; **49**: 3382–6.

496 39. Ciofu O, Riis B, Pressler T, *et al.* Occurrence of hypermutable *Pseudomonas aeruginosa* in  
497 cystic fibrosis patients is associated with the oxidative stress caused by chronic lung  
498 inflammation. *Antimicrob Agents Chemother* 2005; **49**: 2276–82.

499 40. García-Castillo M, Máiz L, Morosini MI, *et al.* Emergence of a *mutL* mutation causing  
500 multilocus sequence typing- pulsed-field gel electrophoresis discrepancy among *Pseudomonas*  
501 *aeruginosa* isolates from a cystic fibrosis patient. *J Clin Microbiol* 2012; **50**: 1777–8. Available  
502 at: <https://pubmed.ncbi.nlm.nih.gov/22322352/>. Accessed August 11, 2021.

503

504

505

## Legends to Figures

**Figure 1.** Susceptibility rates to 12 antipseudomonal agents (A), and prevalence of MDR/XDR/PDR (B) and DTR (C) profiles among 402 *P. aeruginosa* isolates (one per patient) from the ASPIRE-ICU study.

**Figure 2.** Prevalence of MDR/XDR/PDR profiles for the 11 countries participating in the ASPIRE-ICU study.

**Figure 3.** (A) Comparative analysis of susceptibility profiles between paired PAS and respiratory samples from 45 patients. (B) Comparative analysis of susceptibility profiles between paired early and late isolates from 118 patients/sample types.

**Figure 4.** Prevalence (%) of  $\beta$ -lactam resistance mechanisms among 402 *P. aeruginosa* isolates (one per patient) from the ASPIRE-ICU study

**Figure 5.** WGS resistome analysis of 54 MDR/XDR/PDR respiratory isolates from the ASPIRE-ICU study. Countries codes: (BG) Bulgaria, (CZ) Czech Republic, (ES) Spain, (NL) Netherlands, (RS) Serbia. Colour codes: Inactivating loss-of-function mutations and well-characterized gain-of-function mutations are indicated in black whereas any other aminoacid substitution are indicated in grey.

**Figure 6.** Rifampicin resistance mutant frequencies and genetic basis for hypermutation for the 105 respiratory isolates from the ASPIRE-ICU study. PAO1 and its *mutS* deficient derivative were used as controls.

**Figure S1.** Susceptibility rates and MDR/XDR/PDR profiles for (A) respiratory (n=105) and (B) PAS (n=297) isolates from the ASPIRE-ICU study.

**Table S1.** Susceptibility profiles and genomic information for the collection of *P. aeruginosa* isolates studied.

**Table 1.** Distribution of acquired resistance determinants and mutated genes among the 105 respiratory isolates and the clones detected in two or more patients.

[illegible]



<i>ampR</i>	8 (7.6)					1				2				2			2
<i>ampR-G154R</i>	2 (1.8)									2							
<i>ampD</i>	12 (11.4)	4					1				1						
<i>ampDh2</i>	4 (3.8)						1	2									
<i>ampDh3</i>	6 (5.7)																
<i>Mpl</i>	6 (5.7)										1						
<i>oprD</i>	52 (49.5)	27	2	6			1			2						2	
<i>oprD-630Δ1</i>	15 (14.3)	15															
<i>oprD-1301Δ1</i>	3 (2.9)	3															
<i>oprD-W65X</i>	5 (4.8)	5															
<i>oprD-W138X</i>	2 (1.9)		2														
<i>oprD-Q142X</i>	2 (1.9)									2							
<i>oprD-W277X</i>	3 (2.8)						1									2	
<i>oprD-G316D</i>	6 (5.7)			6													
<i>oprD-G916D</i>	4 (3.8)	4															
<i>gyrA</i>	55 (52.4)	33	1	6	1	1	2		2	2				2			
<i>gyrA-T83I</i>	54 (51.4)	33	1	6	1	1	2		2	2				2			
<i>gyrB-S466F</i>	1 (0.9)																
<i>parC</i>	44 (41.9)	29	1	6		1	1		2	2				1			
<i>parC-S87L</i>	43 (41.0)	29	1	6		1	1		2	1				1			
<i>parE</i>	7 (6.7)	4							2					1			
<i>parE-S457G</i>	4 (3.8)	4															
<i>parE-E459G</i>	2 (1.9)								2								
<i>parS</i>	23 (21.9)	8					1	2	2								2
<i>parS-L137P</i>	3 (2.9)								2								
<i>ParR</i>	6 (5.7)						1						2				

<i>parR-M59I</i>	1 (0.9)																
<i>pmrA</i>	1 (0.9)																
<i>pmrB</i>	2 (1.9)																
<i>galU</i>	1 (0.9)						1										
<i>fusA1</i>	4 (3.8)															2	

532


533

**Table 2.** Distribution of the resistance genotypic scores values among 102 *P. aeruginosa* respiratory isolates.

Antibiotic <sup>a</sup>	N (%) Isolates S/I/R <sup>b</sup>		
	Score <0.5 (susceptible genotype)	Score 0.5 - <1 (undetermined genotype)	Score ≥1 (Resistant genotype)
<b>CAZ</b>	44 (100)/ 0 (0)	7 (58.3)/ 5 (41.7)	2 (4.3)/ 44 (95.7)
<b>TOL/Tz</b>	58 (100)/ 0 (0)	1 (33.3)/2 (66.6)	0(0)/ 41 (100)
<b>MER</b>	30 (90.9)/ 2(6.1) / 1(3)	12 (60)/ 7 (35)/ 1 (5)	0 (0)/ 3 (6.1)/ 46 (93.9)
<b>CIP</b>	33 (100)/ 0 (0)	9 (81.8)/ 2 (18.2)	1 (1.7)/ 57 (98.3)
<b>TOB</b>	51 (100)/ 0 (0)	9 (100)/ 0 (0)	0 (0) / 42 (100)


<sup>a</sup> CAZ, ceftazidime; TOL/Tz ceftolozane/tazobactam; MER, meropenem; CIP, ciprofloxacin; TOB, tobramycin

<sup>b</sup> I/R for CAZ and CIP, S/R for TOL/Tz and TOB, S/I/R for MER according to EUCAST breakpoints




**Figure 1.** Susceptibility rates to 12 antipseudomonal agents (A), and prevalence of MDR/XDR/PDR (B) and DTR (C) profiles among 402 *P. aeruginosa* isolates (one per patient) from the ASPIRE-ICU study.






**Figure 2.** Prevalence of MDR/XDR/PDR profiles for the 11 countries participating in the ASPIRE-ICU study.



**Figure 3.** (A) Comparative analysis of susceptibility profiles between paired PAS and respiratory samples from 45 patients. (B) Comparative analysis of susceptibility profiles between paired early and late isolates from 118 patients/sample types.

558




559

560

561 **Figure 4.** Prevalence (%) of  $\beta$ -lactam resistance mechanisms among 402 *P. aeruginosa* isolates (one per patient) from the  
ASPIRE-ICU study

[illegible]

**Figure 5.** WGS resistome analysis of 54 MDR/XDR/PDR respiratory isolates from the ASPIRE-ICU study. Countries codes: (BG) Bulgaria, (CZ) Czech Republic, (ES) Spain, (NL) Netherlands, (RS) Serbia. Colour codes: Inactivating loss-of-function mutations and well-characterized gain-of-function mutations are indicated in black whereas any other aminoacid substitution are indicated in grey.



**Figure 6.** Rifampicin resistance mutant frequencies and genetic basis for hypermutation for the 105 respiratory isolates from the ASPIRE-ICU study. PAO1 and its *mutS* deficient derivative were used as controls.